[go: up one dir, main page]

PL2448968T3 - Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta - Google Patents

Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta

Info

Publication number
PL2448968T3
PL2448968T3 PL10739701T PL10739701T PL2448968T3 PL 2448968 T3 PL2448968 T3 PL 2448968T3 PL 10739701 T PL10739701 T PL 10739701T PL 10739701 T PL10739701 T PL 10739701T PL 2448968 T3 PL2448968 T3 PL 2448968T3
Authority
PL
Poland
Prior art keywords
terminaltruncated
protofibrils
amyloid
oligomers
antibodies selective
Prior art date
Application number
PL10739701T
Other languages
English (en)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda SÖDERBERG
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of PL2448968T3 publication Critical patent/PL2448968T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL10739701T 2009-06-29 2010-06-29 Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta PL2448968T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
EP10739701.0A EP2448968B1 (en) 2009-06-29 2010-06-29 ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (1)

Publication Number Publication Date
PL2448968T3 true PL2448968T3 (pl) 2021-09-13

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10739701T PL2448968T3 (pl) 2009-06-29 2010-06-29 Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta

Country Status (16)

Country Link
US (2) US20120100129A1 (pl)
EP (2) EP3892633A1 (pl)
JP (3) JP2012532094A (pl)
AU (1) AU2010267640B2 (pl)
CA (1) CA2765602C (pl)
CY (1) CY1124034T1 (pl)
DK (1) DK2448968T3 (pl)
ES (1) ES2864049T3 (pl)
HR (1) HRP20210611T1 (pl)
HU (1) HUE053949T2 (pl)
LT (1) LT2448968T (pl)
PL (1) PL2448968T3 (pl)
PT (1) PT2448968T (pl)
SI (1) SI2448968T1 (pl)
SM (1) SMT202100237T1 (pl)
WO (1) WO2011001366A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
BR112013023211B1 (pt) * 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
SI3166970T1 (sl) 2014-07-10 2021-09-30 Bioarctic Ab Izboljšana A-beta protofibril vezavna protitelesa
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
AU2017297804A1 (en) 2016-07-14 2019-01-24 Bioarctic Ab Brain delivery protein
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CA3107370A1 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
WO2021006212A1 (ja) * 2019-07-08 2021-01-14 テルモ株式会社 ハイブリドーマおよびその製造方法、並びにモノクローナル抗体およびその製造方法
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
FI4172199T3 (fi) 2020-06-26 2025-08-12 Bioarctic Ab Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet
WO2023283650A1 (en) 2021-07-09 2023-01-12 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023034230A1 (en) 2021-08-30 2023-03-09 Eisai R&D Mangement Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
EP1571158B1 (en) * 1999-08-04 2009-10-14 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
BR122019012028B1 (pt) * 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
ME01026B (me) * 2007-11-16 2012-10-20 Univ Rockefeller Antitijela specifična za protofibrilni oblik beta-amiloid proteina
JP5747414B2 (ja) * 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン

Also Published As

Publication number Publication date
US20230295283A1 (en) 2023-09-21
CA2765602A1 (en) 2011-01-06
CA2765602C (en) 2021-05-25
SMT202100237T1 (it) 2021-05-07
CY1124034T1 (el) 2022-05-27
JP2019218362A (ja) 2019-12-26
WO2011001366A1 (en) 2011-01-06
JP2012532094A (ja) 2012-12-13
SI2448968T1 (sl) 2021-07-30
LT2448968T (lt) 2021-05-10
EP2448968A1 (en) 2012-05-09
JP6884025B2 (ja) 2021-06-09
EP2448968B1 (en) 2021-01-27
DK2448968T3 (da) 2021-04-12
EP3892633A1 (en) 2021-10-13
HUE053949T2 (hu) 2021-08-30
JP2017197531A (ja) 2017-11-02
AU2010267640B2 (en) 2015-03-05
ES2864049T3 (es) 2021-10-13
AU2010267640A1 (en) 2012-01-19
HRP20210611T1 (hr) 2021-05-28
PT2448968T (pt) 2021-04-30
US20120100129A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
SMT202100237T1 (it) Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali
ZA201202299B (en) Method for decreasing immunigenicity
GB0905140D0 (en) Method
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
GB0902476D0 (en) Method
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
IL215234A0 (en) Method for purifying recombinant fsh
GB0901444D0 (en) Method
PL2114996T3 (pl) Sposób otrzymywania hipoalergenów
IL208514A0 (en) Process for preparing substituted biphenylanilides
GB0905367D0 (en) Method
GB0903316D0 (en) Method
IL217192A0 (en) Biorefinery method
ZA201203155B (en) Method for isolating methylglycinenitrile-n,n-diacetonitrile
PL2284468T3 (pl) Sposób suszenia zrębków
GB0902034D0 (en) Method
GB0904946D0 (en) Method
GB0900560D0 (en) Method
EP2433942A4 (en) PROCESS FOR THE PREPARATION OF D-BIOTIN
GB0903026D0 (en) Novel method
GB0905332D0 (en) Method
GB2476082B (en) Improved base station architecture
IL199690A0 (en) Hanger for fhelf
GB0922292D0 (en) Novel Method